The concentrations of high-and low-density-lipoprotein cholesterol and triglycerides are influenced by smoking, but it is unknown whether genetic associations with lipids may be modified by smoking. We conducted a multi-ancestry genome-wide gene-smoking interaction study in 133,805 individuals with follow-up in an additional 253,467 individuals. Combined metaanalyses identified 13 new loci associated with lipids, some of which were detected only because association differed by smoking status. Additionally, we demonstrate the importance of including diverse populations, particularly in studies of interactions with lifestyle factors, where genomic and lifestyle differences by ancestry may contribute to novel findings.
L evels of serum lipids, such as triglycerides and high-and lowdensity-lipoprotein cholesterol (HDL and LDL), are influenced by both genetic and lifestyle factors. Over 250 lipid-associated loci have been identified [1] [2] [3] [4] [5] [6] , yet it is unclear to what extent lifestyle factors modify the effects of these variants or those of variants yet to be identified. Smoking is associated with an unfavorable lipid profile 7, 8 , warranting its investigation as a lifestyle factor that potentially modifies genetic associations with lipids. Identifying interactions through traditional 1-degree-of-freedom (1df) tests of SNP × smoking terms may have low power, except in very large sample sizes. To enhance power, a 2-degree-of-freedom (2df) test that jointly evaluates interaction and main effects was developed 9 . The Gene-Lifestyle Interactions Working Group, under the aegis of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium 10 , was formed to conduct analyses of lifestyle interactions in the genetic basis of cardiovascular traits. As both genetic and lifestyle factors differ across populations of different ancestry, and to address the under-representation of non-European populations in genomic research, great effort went into creating a large multi-ancestry resource for these investigations 11 . Here we report a genome-wide interaction study that uses both the 1df test of interaction and the 2df joint test of main and interaction effects to examine the hypothesis that genetic associations with serum lipids differ by smoking status.
Results
New loci. We conducted genome-wide interaction meta-analyses for current and ever-smoking status in up to 133,805 individuals of European (EUR), African (AFR), Asian (ASN), and Hispanic (HISP) ancestry (stage 1; Supplementary Tables 1-3) , with followup of 17,921 variants associated at P ≤ 1 × 10 −6 (not pruned for linkage disequilibrium, LD) in an additional 253,467 individuals of EUR, AFR, ASN, HISP, and Brazilian (BR) ancestry (stage 2; Supplementary Tables 4-6), as detailed in Fig. 1 . Of the 17,921 variants associated in stage 1, 16,389 (in 487 loci, defined as the region located ±1 Mb with respect to the variant) passed filters and were included in stage 2 analyses. Ninety percent of variants (14, 733 ) and 22% of loci (109) replicated in stage 2 (variants, P < 0.05/16,389; loci, P < 0.05/487). We conducted meta-analyses of stage 1 and 2 results (Manhattan plots, Supplementary Fig. 1 ; quantile-quantile plots, Supplementary Fig. 2 ) and identified 13 new loci associated at P < 5 × 10 −8 that were at least 1 Mb away from previously reported lipid-associated loci (Table 1 ; results by stage, Supplementary Table 7; forest plots, Supplementary Figs. 3 and 4; regional association plots, Supplementary Fig. 5 ). These loci had low false-discovery rate (FDR) q values (all q < 3 × 10 −4
; Supplementary Table 8) . We report the new loci associated at P < 5 × 10 −8 as well as those among these passing a more stringent significance threshold (P < 6.25 × 10 ), adjusted for two smoking exposures, two interaction tests, and ancestry-specific and trans-ancestry tests. The patterns observed in these results are described below and illustrated with output from stage 1 meta-analyses, where results from a main-effect model (in all individuals and with stratification by smoking exposure) and a smoking-adjusted main-effect model were also available ( Fig. 1 and Supplementary Table 9) .
Notably, many of the new loci were statistically significant only in AFR meta-analyses. For 7 of the 13 new loci, the minor allele frequency (MAF) of the index variant was highest in AFR populations, and inter-ancestry differences in MAF and/or LD may explain the inability to detect similar associations in the other ancestry groups. However, some AFR-only associations were unlikely to be due to diminished power in non-AFR meta-analyses. For instance, the effect of rs12740061 (NC_000001.10:g.694078 10C>T; LOC105378783) on HDL was significantly modified by current smoking status among AFR individuals (P 1df = 7.4 × 10 −9 ; Fig. 2 and Table 1 ), such that the genetic effect was stronger among current smokers than among nonsmokers (Supplementary Table 9 ). In contrast, there was virtually no evidence for association in any other ancestry group, despite these groups having higher MAF values for the variant (Fig. 2) . The potential influence of underadjustment for principal components on these results was evaluated by excluding the six studies that adjusted for only 1 principal component (the average number of principal components adjusted for among AFR studies was 4.2); in this analysis, effect estimates were similar and P values were increased or similar in comparison to the original analysis, in line with the ~20% reduction in sample size (Supplementary Table 10 ).
We observed interactions where notable associations were only found among current or ever-smokers, with effect sizes close to zero among non-or never-smokers, including a statistically significant association in the 2df joint test of main and interaction effects of rs7364132 (NC_000022.10:g.20096172G>A; DGCR8) × ever smoking with triglycerides (P 2df = 2.5 × 10 −8 ; Table 1 ). Main-effect models stratified by smoking status showed a strong A full list of authors and affiliations appears at the end of the paper.
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NATure GeNeTiCs genetic association with triglycerides among ever-smokers (difference in mean ln(triglycerides) per A allele (β) = −0.05, P = 7.9 × 10 −8 ), with a negligible association among never-smokers (β = 0.01, P = 0.19; Fig. 3 ). This association was not significant in the non-stratified main-effect model (Table 1 and Supplementary  Table 9 ) and was only detectable when modeling permitted different associations across smoking strata. Similar results were observed for rs79950627 (NC_000011.9:g.2233790G>A; MIR4686) × current smoking with LDL and rs56167574 (NC_000007.13:g.15124597 5G>A; PRKAG2) × ever smoking with LDL ( Fig. 3 and Supplementary Table 9 ).
We also observed interactions where effects were in opposite directions in the exposed and unexposed strata, with a larger effect and more statistically significant association among smokers. For instance, current smoking status modified the association between rs73453125 (NC_000007.13:g.146084573G>A; CNTNAP2) and LDL (Table 1 ). In stratified main-effect models, the A allele was associated with lower LDL among current smokers (β = −8.1 mg/ dl, P = 2.2 × 10 −7
) but was associated with higher LDL among nonsmokers (β = 2.18 mg/dl, P = 0.01; Fig. 4a and Supplementary Table 9 ). In a non-stratified smoking-adjusted main-effect model, no association between rs73453125 and LDL was detected (β = 0.3 mg/dl, P = 0.98). Similar results were observed for rs12740061 (LOC105378783) (Supplementary Table 9) .
Although many interactions manifested as associations that were only significant or were stronger in smokers, for rs10937241 (NC_000003.11:g.185822774A>G; ETV5), rs34311866 (NC_0000 04.11:g.951947T>C; TMEM175), rs10101067 (NC_000008.10:g.72 407374G>C; EYA1), and rs77810251 (NC_000007.13:g.121504149 G>A; PTPRZ1), the associations observed among non-or neversmokers were more statistically significant. Notably, in stratified main-effect models, rs77810251 was associated with increased HDL among never-smokers (β = 0.05 ln(HDL), P = 6.3 × 10
−11
) with no significant association among ever-smokers (β = −0.005 ln(HDL), P = 0.56; Fig. 3 and Supplementary Table 9 ). In a smoking-adjusted main-effect model of never-and ever-smokers together, the association was markedly reduced (β = 0.02 ln(HDL), P = 1.6 × 10
−4
). The 2df joint test simultaneously evaluates main effects and smoking interaction effects; some of our results seem to capture a main effect of the variant. For instance, the 2df test for rs12144063 (EYA3) detected an association (P = 1.3 × 10 −10 ), whereas the 1df test of interaction did not (P = 0.75). The minor alleles for this and three other variants (rs10937241 (ETV5), rs34311866 (TMEM175), and rs10101067 (EYA1)) were common across populations and reached genome-wide statistical significance despite effects being small in magnitude (rs10101067 (EYA1); Fig. 4b ), in agreement with expectations for new main-effect loci in well-studied populations. There were two findings, however, for which the relatively large sample size in the AFR meta-analyses seemed to facilitate detection. For rs73729083 (NC_000007.13:g.137559799T>C; CREB3L2), the MAF was much greater in AFR than in HISP or ASN populations (not present in EUR populations) and variant effect estimates were large and consistent across ancestry groups, whereas interaction effect estimates were inconsistent, with wide confidence intervals ( Supplementary Fig. 3f ). At rs4758675 (NC_000012.11:g.12269173 8C>A; B3GNT4), the minor allele was only present in AFR populations ( Supplementary Fig. 3k ), but variant effect estimates were consistent across AFR studies, with interaction effect estimates Summary of data included in this study. Of the 17,921 associated variants from stage 1, 16,389 passed filtering criteria and were included in stage 2 analyses. Trans-ancestry combined stage 1 and 2 meta-analyses were performed on stage 1 trans-ancestry and stage 2 trans-ancestry meta-analyses and not on combined ancestry-specific analyses from stage 1 and stage 2. In models, 1df terms are in bold and 2df terms are underlined. TRANS, trans-ancestry. Model descriptions include terms for the outcome (γ), intercept (β 0 ), covariates (β C C), the variant (β G SNP), smoking status (β E E), and interaction of the variant and smoking status (β GE E × SNP).
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NATure GeNeTiCs approaching the null (Supplementary Fig. 4e ). In total, 6 of the 13 new loci that we identified seem to be driven by main effects of the variant while the remainder show some evidence of interaction with smoking.
There were 16 additional new loci identified in stage 1 metaanalyses (P 1df or P 2df < 5 × 10 −8
) for which the variants were unavailable for analysis in stage 2 cohorts. These loci were identified only in AFR meta-analyses (many were AFR-specific variants; Table 2 ). Because of the relatively small number and size of the available AFR cohorts in stage 2 (total n = 7,217 individuals; n < 2,000 per cohort), these relatively low-frequency variants did not pass filters for minor allele count within exposure groups. Nevertheless, associations for these variants had low FDR q values (all q < 2.4 × 10 −4 ) in stage 1, and some seem worthy of further investigation. One particularly interesting example is the association of rs17150980 (NC_00000 7.13:g.78173734T>C; MAGI2) × ever smoking with triglycerides (P 2df = 1.4 × 10 ), in which consistent effects were observed for both the variant and the interaction across AFR studies but not in other ancestry groups ( Supplementary Fig. 6 ).
As we ran analyses for both current and ever-smoking status, we evaluated new associations across smoking exposures to further characterize these loci (Supplementary Table 11 ). For the six probable main-effect loci (EYA3, ETV5, TMEM175, CREB3L2, EYA1, and B3GNT4), an association of similar statistical significance was observed across smoking status definitions for the 2df joint test with a similar lack of effect for the 1df test of interaction, in agreement with the interpretation that smoking status was unimportant and only the main effect drove association. For the locus in which a stronger association was observed among nonsmokers (PTPRZ1), the 1df interaction P value was dramatically reduced from 9.5 × 10 −7 for ever smoking to 0.011 for current smoking, in line with any smoke exposure altering the association between this variant and HDL and the notion that including former smokers with never-smokers (as in the analysis of current smoking) dilutes the observed association among never-smokers. For the reported interactions with current smoking, all effect estimates were greatly reduced in the ever-smoking analysis, suggesting that active smoking is the relevant exposure. For the reported interactions with ever smoking, markedly reduced statistical significance was observed in the analysis of current smoking, likely reflecting a drop in power from excluding former smokers from the exposed group.
We conducted a secondary analysis of smoking dose in two of our AFR cohorts with measured cigarettes per day for four interaction loci (see the Methods for selection criteria): rs12740061 (LOC105378783), rs73453125 (CNTNAP2), rs79950627 (MIR4686), and rs7364132 (DGCR8). For each of these variants, a stronger association was observed with increasing smoking dose (Supplementary Table 12 ), and the interaction was statistically significant for all variants but rs7364132, for which the P value was just over our threshold for statistical significance (P = 0.0035 versus P < 0.0021).
Conditional analysis showed no evidence that the new associations were driven by variants at known lipid-associated loci (Supplementary Table 13 ). Imputation quality for the new variants was high (minimum of 0.75), with sample-size-weighted average imputation quality of 0.90, and MAFs match those in publicly available datasets (Supplementary Table 14 ).
Interactions at known loci. We examined interactions with smoking at known lipid-associated loci. Because results for the 2df test at known loci are expected to predominantly reflect previously identified main effects, we exclusively evaluated results from the 1df test of interaction. No interactions within known loci were statistically significant (P 1df < 0.05/269 known loci in our data). To evaluate whether the proportion of known variants with P 1df < 0.05 was higher than would be expected by chance (5%), we conducted binomial tests for each trait-exposure combination (P values were Bonferroni corrected for multiple tests). There was significant enrichment for known variants with interaction in the 1df test reaching P < 0.05, including for the HDL-current smoking (P = 9.6 × 10 ), and triglyceridesever smoking (P = 3.1 × 10 −4 ) combinations. We conducted power calculations under different interaction scenarios to determine the conditions under which an interaction analysis and a maineffect analysis would both be sufficiently powered to detect the same locus (that is, when an interaction could be detected in a locus previously identified in a main-effect analysis; Supplementary Table 15 ). At current trans-ancestry meta-analysis sample sizes and when assuming a large effect size, there was limited power to detect either a main effect or an interaction when an association was of larger effect or only present among smokers (main effect, <1%; interaction, 77%) or when associations differed in magnitude but not direction (main effect, >99%; interaction, <1%), thus making it unlikely that an interaction at a known locus would be detected. We were well powered for both interaction and main-effect analyses to detect smoking interactions in which smoking eliminated or drastically reduced an association with a large effect size among non-or never-smokers. We identified one such interaction in our data, for PTPRZ1 in AFR studies only, which may not have previously been identified in a main-effect analysis because of the limited power of AFR main-effect analyses thus far.
Proportion of variance explained by the identified loci.
Ten studies from four ancestry groups were used to calculate the proportion of the variance in lipid traits explained by the new genomewide-significant loci, including 13 loci from combined stage 1 and 2 meta-analyses (Table 1 ) and 16 loci from stage 1 that were not available in stage 2 analyses (Table 2) . Two different methods were used (Methods), and the range of findings across these methods is presented (Supplementary Table 16 ). In the AFR ancestry group, the new variants and their interactions explained 1.0-2.7% of variance in HDL, 0.7-2.6% of variance in LDL, and 1.3-3.2% of variance in triglycerides. The proportion explained was smaller among EUR (0.06-0.14% for HDL, 0.01-0.07% for LDL, and 0.10-0.19% for triglycerides), ASN (0.27-0.86% for HDL, 0.09-0.82% for LDL, and 0.8-1.5% for triglycerides), and HISP (0.2-0.4% for HDL, 0.2-0.5% for LDL, and 0.2-0.4% for triglycerides) ancestry groups. These results should be considered in the context of the differences in MAF between the ancestry groups: the proportion of new variants that could be evaluated varied by ancestry group, with 94-97% of variants available for analysis in the AFR cohorts, but only 32-39% of variants available in the EUR and ASN cohorts and 55% of variants available in the HISP cohort. In contrast, each of the cohorts investigated had a similar proportion of the known variants considered (83-96%).
Reproducing known lipid associations. We evaluated the degree to which our data reproduce previously reported lipid-associated loci. Given that approximately 81% of the cohorts in stage 1 were also included in previous efforts, this analysis is not a formal replication. For comparability with traditional genome-wide association studies (GWAS), we evaluated results from stage 1 maineffect models. Of the 356 previously reported associations for 279 variants (compiled from refs. [1] [2] [3] [4] [5] [6] 12 ), there were 236 associations for 189 variants that were confirmed in our data (with consistent direction of effect and P < 0.05/356), for a 66.3% concordance rate (Supplementary Table 17 ).
Bioinformatics.
To characterize the potential impact of our new associations on chronic disease risk and to investigate biological mechanisms, we conducted a series of follow-up analyses and Frequency of the tested allele in 1000 Genomes data by ancestry: Asian (ASN), Americas (AMR), African (AFR), and European (EUR). c If a region was associated with a trait in more than one meta-analysis, the most statistically significant result is listed first and described in the table. d
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P values from a smoking-adjusted main-effect model (available in stage 1 cohorts only; Fig. 1 ). e Statistically significant when using a stricter P-value threshold, after Bonferroni correction for two smoking traits, two interaction tests, and ancestry and trans-ancestry testing (P < 5 × 10 −8 /8 = 6.25 × 10 −9
).
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annotations. We performed extensive bioinformatics annotation of variants within the 29 new loci (Tables 1 and 2 ). These loci included 78 associated variants that were in or near 33 unique genes (Supplementary Table 18 ). We performed lookup of these variants in previously conducted GWAS for related traits (Supplementary  Tables 19-24) , the Genotype-Tissue Expression (GTEx) portal (v7.0) and RegulomeDB (Supplementary Table 25 ), HaploReg v4.1 (Supplementary Table 26) , and an analysis of cis and trans expression quantitative trait loci (eQTLs) in whole blood from Framingham Heart Study participants (Supplementary Table 27 ). Additionally, for each trait, we performed DEPICT gene prioritization (Supplementary Tables 28-30) , gene set enrichment analysis (Supplementary Tables 31-33) , and tissue or cell type enrichment analysis 13 (Supplementary Tables 34-37 ), in which we used both new and known loci. Notable findings from these follow-up analyses are summarized below by locus.
In line with our observations of an association of the C allele at rs10101067 (EYA1) with higher triglyceride levels, this allele was associated with increased risk of coronary artery disease (β = 0.036, P = 0.03; Supplementary Table 19) , ischemic stroke (β = 0.11, P = 0.04; Supplementary Table 20) , and higher waist-to-hip ratio adjusted for body mass index (BMI) (β = 0.029 units, P = 6.5 × 10
; similar results were observed for waist circumference adjusted for BMI; Supplementary Table 21) .
We found an association of the T allele at rs12144063 (NC_000 001.10:g.28406047G>T; EYA3) with lower HDL levels. This allele was associated with increased risk of all stroke types (β = 0.05, P = 0.04), as well as stroke subtypes (Supplementary Table 20) . rs7529792 (NC_000001.10:g.28306250C>T), a variant in LD with rs12144063 (r 2 = 0.97), regulates gene expression of EYA3 and has a high RegulomeDB score (1b; Supplementary Table 25) . HaploReg also showed regulatory features for rs12144063, identifying it as being in a promoter region expressed in liver and brain, in enhancer histone marks, and in DNase marks for EYA3 (Supplementary  Table 26 ). DEPICT predicted a role for these variants in regulating expression of EYA3 and XKR8 (Supplementary Table 28 ), the latter of which encodes a phospholipid scramblase important in apoptotic signaling 14 .
We report an interaction between smoking and rs77810251 (PTPRZ1), in which the minor allele is associated with higher HDL levels only among never-smokers. Although this variant was not available for lookup in data from the Genetic Investigation of Anthropometric Traits (GIANT) consortium, a variant in this locus with a similar association, rs740965 (NC_000007.13:g.1215135 61T>G), was associated with lower BMI among EUR individuals (β = −0.01 kg/m 2 , P = 0.01; similar results were observed for transancestry analysis). This variant was also associated with lower waist circumference adjusted for BMI among EUR women (β = −0.016, P = 0.04; Supplementary Table 21) . PTPRZ1 was shown to be downregulated in cells treated with an acute dose of nicotine 15 , which supports our observation of a lack of association of PTPRZ1 variants among ever-smokers. For select variants for which an association was primarily observed in only one smoking stratum, we compare the P values for stage 1 linear association models, including a main-effect model adjusted for age, sex, principal components, and study-specific covariates (as appropriate) in all individuals and with stratification by smoking exposure; a model additionally adjusted for smoking exposure; and a model that also included a smoking exposure × SNP interaction term, from which a 1df test of interaction and a 2df joint test of main effect and interaction were calculated. Associations are shown, from left to right, for rs7364132 (DGCR8) × ever smoking and triglycerides (n = 21,834; 11,113 neversmokers, 10,725 ever-smokers), rs79950627 (MIR4686) × current smoking and LDL (n = 23,348; 18,384 nonsmokers, 4,973 current smokers), rs56167574 (PRKAG2) × ever smoking and LDL (n = 23,353; 11,700 neversmokers, 11,649 ever-smokers), and rs77810251 (PTPRZ1) × ever smoking and HDL (n = 23,146; 11,560 never-smokers, 11,592 ever-smokers).
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We report a main effect for rs34311866 on HDL and triglyceride levels. rs34311866 encodes a missense variant in TMEM175, which has been associated with Parkinson's disease 16 and type 2 diabetes ) and is an eQTL for DGKQ in adipose, artery, lung, nerve, and thyroid tissues (Supplementary Table 25 ). Expression of DGKQ is more strongly regulated by another significantly associated variant in this locus, rs4690220 (NC_000004.11:g.980464A>G), which is located upstream of IDUA and in an intron of SLC26A1. This variant had a high score in RegulomeDB (1f), supporting the idea that it potentially has a functional effect (Supplementary Table 25 [21] [22] [23] [24] . The DGKQ protein interacts with the key lipid enzymes LPL, LIPG, and PNPLA3 ( Supplementary Fig. 7 ). These results suggest that the observed association with HDL and triglycerides could act on cholesterol metabolism through regulation of DGKQ. Also, rs34311866 is a trans eQTL for GNPDA1 (Supplementary Table 27 ); expression of this gene has been associated with a set of traits, including hyperlipidemia 25 . In our data, there was a significant interaction between rs12740061 (LOC105378783) and smoking, such that the minor allele was associated with decreased HDL levels only among current smokers. This variant is a trans eQTL for TAS1R1 (Supplementary  Table 27 ). Variants in this gene have been found to influence taste receptors, notably affecting cigarette smoking habits 26 .
Discussion
In this study, we evaluated gene-smoking interactions in large, multi-ancestry meta-analyses of serum lipids, while using varying associations among smoking subgroups to improve the ability to detect new lipid-associated loci. We report 13 new loci for serum lipids from stage 1 and 2 meta-analyses. Sixteen additional statistically significant new loci were found in stage 1 but were unavailable for analysis in stage 2. All 29 new associations had a low q value (P < 3 × 10
−4
). Using both the 1df test of interaction and the 2df joint test of main and interaction effects in this study allowed us to improve our inferences on the basis of the results: the 2df test bolstered the power to detect interactions, while the 1df test could discriminate between associations that predominantly reflected main effects versus interactions.
Our results provide support for future efforts to evaluate lifestyle interactions with complex traits. We identified loci for which an association with serum lipids was only observed in one smoking stratum. In main-effect models of these loci, the signal from one subgroup was not detected when all individuals were evaluated together (regardless of adjustment for smoking). These loci could only be observed through analysis that was stratified by smoking status or contained an interaction term, highlighting the importance of considering potential effect modification in association studies. Additionally, through use of the joint 2df test, we identified six loci that seem to represent new main effects. In agreement with this characterization, five of these loci were within 500 kb of variants identified in recent large-scale association studies that used main-effect models: ETV [27] [28] [29] , TMEM175 (ref. ). With 23,753 AFR individuals in the stage 1 analyses and 30,970 AFR individuals overall, this work represents one of the largest studies of serum lipids in AFR cohorts. It is therefore not surprising that two of our new lipid-associated loci (CREB3L2 and B3GNT4) seem to be driven primarily by genetic main effects. Notably, these associations could not have been detected in EUR individuals, as the tested allele for both rs4758675 (B3GNT4) and rs73729083 (CREB3L2) is absent in EUR populations.
In addition to these probable main-effect loci, the prominence of the new loci that were statistically significant only in AFR metaanalyses deserves further discussion. Some findings could not be effectively evaluated in other ancestry groups because of differences in MAF between the ancestry groups, with the minor alleles for half of the variants much more frequent in AFR populations. More puzzling, however, is the discovery of loci with evidence of strong interactions in the AFR ancestry group but not in meta-analyses in other ancestry groups, despite comparable or higher allele frequencies in these groups, such as were observed for rs12740061 (LOC105378783; Fig. 2 ) or rs17150980 (MAGI2; 
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NATure GeNeTiCs Supplementary Fig. 6 ). This phenomenon suggests inter-ancestry differences in genomic or environmental context. There are variants in LD (r 2 > 0.2) with rs12740061 (LOC105378783) and rs17150980 (MAGI2) in AFR populations that are not in LD with these variants in other ancestry groups 30 , but these variants were directly tested in our study with no evidence of association in non-AFR analyses. Thus, it is unlikely that inter-ancestry differences in LD explain these results, although unmeasured causal variants are a possibility. Interancestry differences in smoking are also a potential explanation. In addition to known differences in smoking patterns 31 , there are pronounced differences between ancestry groups in preferred cigarette type, with over 85% of AFR smokers using menthol cigarettes as compared to 29% of EUR smokers (in the United States) 32 . Menthol cigarettes are thought to facilitate greater absorption of harmful chemicals because of deeper inhalation 31, 33 , through desensitization of the nicotinic acetylcholine receptors that cause nicotine-induced irritation 34 . Evidence for an excess risk of cardiovascular disease associated with mentholated cigarettes, however, is equivocal [35] [36] [37] [38] [39] . Ancestry differences in smoking-related metabolites and carcinogens have been reported [40] [41] [42] [43] , and differential metabolism of key compounds may underlie observed differences by ancestry group. Some behaviors or conditions that co-occur with smoking may also differ by ancestry, and this additional factor may modify observed genetic associations with serum lipids.
The biological mechanisms through which smoking influences observed genetic associations will require further investigation, as the myriad components of cigarette smoke and their downstream consequences (including oxidative stress and inflammation) affect pathways throughout the body 44 . However, there is evidence for differential expression of PTPRZ1 (ref. 
0.17
All loci shown in the table have some evidence of interaction (P < 0.05 in 1df test of interaction); thus, results are not categorized into 'loci with evidence for interaction' and 'probable main-effect loci (no evidence for interaction)' as in Table 1 . Bolding indicates genome-wide statistical significance. AFR, African; CS, current smoking; ES, ever smoking; SE, standard error; TRIG, triglycerides. a Listed variants represent the lead association within the 1-Mb region for the 2df and 1df tests of variant × smoking interaction after excluding variants within 1 Mb of known lipid-associated loci. If the variant was in or within 2 kb of a gene, the name of that gene is listed. b Frequency of the tested allele in 1000 Genomes data by ancestry: Asian (ASN), Americas (AMR), African (AFR), and European (EUR). c P values from a smoking-adjusted main-effect model (available in stage 1 cohorts only; Fig. 1 ). d Statistically significant when using a stricter P-value threshold, after Bonferroni correction for two smoking traits, two interaction tests, and ancestry and trans-ancestry testing (5 × 10 −8 /8 = 6.25 × 10 −9 ).
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The sample size attained for diverse ancestry groups is a key strength of our study, particularly among AFR studies. As a result, we were able to identify loci that had not been previously detected in meta-analyses of ancestry groups that are better represented in genomic research. Additionally, the use of nested models in our stage 1 analyses allowed us to more fully characterize loci. Despite these strengths, however, a smaller number of AFR studies were available for stage 2, resulting in an inability to follow up on some of our low-frequency findings from stage 1.
In conclusion, this large, multi-ancestry genome-wide study of the effects of gene-smoking interactions on serum lipids identified 13 new loci on the basis of combined analyses of stages 1 and 2 as well as 16 additional new loci on the basis of stage 1 that were unavailable in stage 2. Associations for some loci were detected only in analyses stratified by smoking status or with a smoking interaction term, thus motivating further study of gene × environment interactions for other lifestyle factors to identify new loci associated with lipids and other complex traits. We demonstrate the importance of including diverse populations, attaining a sample size in these analyses sufficient for discovery of new main-effect lipid-associated loci in AFR populations. Careful consideration of ancestry may be of particular importance for gene × environment interactions, as ancestry may be a proxy for both genomic and environmental context. 
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Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41588-019-0378-y. 16 
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Methods
Details regarding the motivation for and methodology of this and other projects of the CHARGE Gene-Lifestyle Interactions Working Group are available in our recently published methods paper 11 , and detailed information on study design can be found in the Reporting Summary.
Participants. Analyses included men and women between 18 and 80 years of age of EUR, AFR, ASN, HISP, and (in stage 2 only) BR ancestry. Participating studies are described in the Supplementary Information, with further details on sample sizes, trait distribution, and data preparation available in Supplementary  Tables 1-6 . Considerable effort was expended to engage as many studies of diverse ancestry as possible. This work was approved by the Washington University in St. Louis Institutional Review Board and complies with all relevant ethical regulations. Each study obtained informed consent from participants and received approval from the appropriate institutional review boards.
Phenotypes. Analyses evaluated the concentrations of HDL, LDL, and triglycerides. LDL could be either directly assayed or derived by using the Friedewald equation (if triglyceride concentration was ≤400 mg/dl and individuals were fasting for at least 8 h). Lipid-lowering drug use was defined as any use of a statin drug or any unspecified lipid-lowering drug after 1994 (when statin use became common). If LDL was directly assayed, adjustment for lipid-lowering drug use was performed by dividing the LDL value by 0.7. If LDL was derived with the Friedewald equation, total cholesterol was first adjusted for lipid-lowering drug use (total cholesterol/0.8) before calculation of LDL by the Friedewald equation. No adjustments were made for any other lipid medication, nor were adjustments made to HDL or triglycerides for medication use. If samples were from individuals who were not fasting (fasting ≤8 h), neither triglycerides nor calculated LDL was used. Both HDL and triglycerides were natural log transformed, while LDL was not transformed. In the event that multiple measurements of lipids were available (in a longitudinal study), analysts selected the visit for which data were available for the largest number of participants and the measurement from that visit was included in analyses.
Environmental exposure status. The smoking variables evaluated were current smoking status (yes/no) and ever-smoking status (yes/no). Current smokers were included in the exposed group for both of these variables, and never-smokers were included in the unexposed group for both of these variables. Former smokers were included in the unexposed group for the current smoking variable and the exposed group for the ever-smoking variable. Smoking variables were coded as 0 and 1 for the unexposed and exposed groups, respectively. Genotype data. Genotyping was performed by each participating study by using genotyping arrays from either Illumina or Affymetrix. Each study conducted imputation with various software. The cosmopolitan reference panel from 1000 Genomes Project Phase I Integrated Release Version 3 Haplotypes (2010-11 data freeze, 2012-03-14 haplotypes) was specified for imputation and used by most studies, with some using the HapMap Phase 2 reference panel instead. Only variants on the autosome and with MAF of at least 0.01 were considered. Specific details of each participating study's genotyping platform and imputation software are described in Supplementary Tables 3 and 6 . Genotype was represented as the dosage of the imputed genetic variant, coded additively (0, 1, or 2).
Stage 1 analysis. Stage 1 genome-wide interaction analyses included 29 cohorts contributing data from 51 study/ancestry groups and up to 133,805 individuals of EUR, AFR, ASN, and HISP ancestry (Supplementary Tables 1-3 ). All cohorts ran three models in all individuals: a main-effect model, a model adjusted for smoking, and an interaction model that included a multiplicative interaction term between the variant and smoking status (Fig. 1) . Additionally, the main-effect model was run with stratification by smoking exposure. All models were run for 3 lipid traits (HDL, LDL, and triglycerides) and 2 smoking exposures (current smoking and ever smoking). Thus, each study/ancestry group completed 30 GWAS (using five models × three traits × two exposures).
All models were adjusted for age, sex, and field center (as appropriate). Principal components derived from genotyped SNPs were included at the study analyst's discretion. All AFR cohorts were requested to include at least the first principal component, and 71% of AFR cohorts used multiple principal components (with 25% using ten). The average number of principal components used was 4.2. Additional cohort-specific covariates could be included if necessary to control for other potential confounding factors. Studies including participants from multiple ancestry groups conducted and reported the results of analyses separately by ancestry group. Participating studies provided the estimated genetic main effects and robust estimates of standard error for all requested models. In addition, for models with an interaction term, studies also reported the interaction effects and robust estimates of their standard errors, as well as a robust estimate of the corresponding covariance matrix between the main and interaction effects. To obtain robust estimates of covariance matrices and robust standard errors, studies with only unrelated participants used either the sandwich or ProbABEL R package. If a study included related individuals, either generalized estimating equations (R package geepack) or linear mixed models (GenABEL, MMAP, or R) were used. Sample code provided to studies to generate these data has previously been published (see the supplementary materials in ref. 11 ). Extensive quality control was performed with EasyQC 49 on the study level (examining the results of each study individually) and then on the ancestry level (examining all studies within each ancestry group together). Study-level quality control consisted of exclusion of all variants with MAF < 0.01, extensive harmonization of alleles, and comparison of allele frequencies with ancestryappropriate 1000 Genomes reference data. Ancestry-level quality control included compilation of summary statistics on all effect estimates, standard errors, and P values across studies to identify potential outliers and production of SE-N and quantile-quantile plots to identify analytical problems (such as improper trait transformations) 50 . Variants were excluded from ancestry-specific meta-analyses for imputation score < 0.5; the same threshold was implemented regardless of the imputation software used, as imputation quality measures have been shown to be similar across software 51 . Additionally, variants were excluded if the minimum of the minor allele count in the exposed or unexposed group × imputation score was less than 20. To be included in meta-analyses, each variant had to be available from at least three studies or 5,000 individuals contributing data.
Meta-analyses were conducted for all models with the inverse-varianceweighted fixed-effects method as implemented in METAL. We evaluated both a 1df test of interaction effect and a 2df joint test of main and interaction effects, following previously published methods 9 . A 1df Wald test was used to evaluate the 1df interaction, as well as the main effect and the smoking-adjusted main effect in models without an interaction term. A 2df Wald test was used to jointly test the effects of both the variant and the variant × smoking interaction 52 . Meta-analyses were conducted within each ancestry group separately, and trans-ancestry metaanalyses were then conducted on all ancestry-specific meta-analyses. Genomic control correction was applied before all meta-analyses.
Variants that were associated in any analysis at P ≤ 1 × 10 −6 were carried forward for analysis in stage 2. A total of 17,921 variants from 519 loci (defined by physical distance of ±1 Mb) were selected for stage 2 analyses.
Stage 2 analysis.
Variants selected for stage 2 were evaluated in 50 cohorts, with data from 75 separate ancestry/study groups in a total of 253,467 individuals (Supplementary Tables 4-6 ). In addition to the four ancestry groups listed above, stage 2 analyses also included studies of BR individuals. BR individuals were considered only in the trans-ancestry meta-analyses, as there were no stage 1 BR results for meta-analysis. In stage 2, variants were evaluated only in the model with an interaction term (Fig. 1) . Study-and ancestry-level quality control were carried out as in stage 1. In contrast to stage 1, no additional filters were included for the number of studies or individuals contributing data to stage 2 meta-analyses, as these filters were implemented to reduce the probability of false positives and were less relevant in stage 2. Stage 2 variants were evaluated in all ancestry groups and for all traits, regardless of which meta-analysis met the P-value threshold in stage 1 analysis. Genomic control was not applied to stage 2 meta-analyses, given the expectation of association. To ensure the quality of analyses, all quality control and meta-analyses of replication data were completed independently by analysts at two different institutions (A.R.B. and J.L.B. at the NIH and E.L., X.D., and C.T.L. at Boston University), with differences resolved through consultation.
Meta-analyses of stages 1 and 2. Given the increased power of combined metaanalyses of stages 1 and 2 in comparison with a discovery and replication strategy 53 , combined stage 1 and 2 meta-analyses were carried out for all selected variants . We report variants significant at 5 × 10 −8 as well as those significant after Bonferroni correction for two smoking traits, two interaction tests, and ancestry-specific and trans-ancestry testing, with a P value of 6.25 × 10 −9 (5 × 10 −8 /8). Loci that were significant at the stricter P-value threshold are indicated in the main tables. Loci were defined on the basis of physical distance (±1 Mb) and are described by the index variant (the most statistically significant variant within each locus). Novelty was determined by physical distance (±1 Mb) from known lipid-associated loci compiled from large meta-analyses [1] [2] [3] [4] [5] 12 . FDR q values were determined with EasyStrata to implement the Benjamini-Hochberg method of calculation. Results were visualized by using R 3.1.0, including the package forestplot ( Supplementary  Figs. 3 and 4) , and with LocusZoom v1.4 ( Supplementary Fig. 5 ) for regional association plots.
Smoking dose analysis.
To further characterize associations, we evaluated an interaction between smoking dose and a few of the new loci. Although data on smoking dose were not available for many of the included studies, we conducted secondary analysis on smoking dose interaction in a subset of loci in our two largest AFR studies: WHI-SHARE and ARIC. We identified four loci from our main results (LOC105378783, CNTNAP2, MIR4686, and DGCR8) for followup on the basis of the following criteria: an interaction locus (as opposed to a probable main effect), stronger association observed among smokers than among non-or never-smokers, and presence of contributing cohort(s) with smoking dose variables available and with P < 0.05 for the reported result (to ensure sufficient power for analysis). We investigated these four loci by using three methods of characterizing cigarettes per day: a quantitative variable, a categorical variable based on meaningful dose levels (less than half a pack, between half a pack and a pack, and more than a pack per day), and a binary variable defined by the median number of cigarettes per day in a cohort. Dose variables were defined separately by smoking status, such that cigarettes per day for former smokers were set to 0 for variables defined for current smokers, while cigarettes per day for both current and former smokers were quantified when defined for ever-smokers. Statistical significance was set at P < 0.0021; Bonferroni correction was performed to account for investigation of four loci, three smoking dose variables, and two smoking exposures.
Conditional analyses.
To assess the independence of new loci from established lipid-associated loci, we conducted conditional analyses with GCTA. GCTA's conditional and joint analysis option (COJO) calculates approximate conditional and joint association analyses on the basis of summary statistics from a GWAS meta-analysis and individual genotype data from an ancestry-appropriate reference sample (for LD estimation). For new loci from predominantly AFR meta-analyses, the LD reference set included unrelated AFR participants from HUFS, CFS, JHS, ARIC, and MESA (total n = 8,425). For new loci from predominantly EUR metaanalyses, the LD reference set included unrelated EUR participants from ARIC (total n = 9,770). With the exception of HUFS, these data were accessed through dbGaP (ARIC, phs000280.v2.p1 and phs000090.v2.p1; CFS, phs000284.v1.p1; JHS, phs000286.v4.p1 and phs000499.v2.p1; MESA, phs000209.v13.p1 and phs000420. v6.p3) and imputed to 1000 Genomes Phase 1 v.3 with the Michigan Imputation Server 54 . For loci with P < 5 × 10 −8 for the 1df test of interaction, results from stage 1 and 2 meta-analyses were adjusted for all known lipid-associated loci. A method for running conditional analyses for 2df tests has not been implemented within GCTA; therefore, we evaluated loci with P < 5 × 10 −8 for the 2df joint test of main and interaction effects by conditioning stage 1 stratified analyses on known lipid-associated loci (stratified analyses were not conducted in stage 2 studies). The conditioned 2df joint test of main and interaction effects was then calculated with EasyStrata 50 on the conditioned stratified results.
Power calculations for detecting interactions at known lipid-associated loci. To better contextualize our lack of detection of an interaction at a known locus, we conducted power calculations under a variety of scenarios. We explored the power to detect both an interaction and a main effect, making assumptions on the basis of our data, as the sample sizes achieved in this project are comparable to those in the largest main-effect GWAS for lipids 1, 5 . By using previously developed analytical power formulas 55 , we evaluated three interaction scenarios: a pure interaction effect (no effect in nonsmokers and a positive effect in current smokers), a quantitative interaction (effects in the same direction across strata but of different magnitude), and a qualitative interaction (effects in opposite directions and of different magnitude). We assumed stage 1 and 2 sample sizes and 19% prevalence for smoking (as in our data). For the purpose of illustration, we assumed relatively large effects explaining 0.06% of variance in the lipid trait; the median variance explained from known lipid-associated loci, as estimated in a previous publication (see Supplementary Table 1 in ref. 2 ), is 0.04%.
Proportion of variance explained.
To evaluate the proportion of variance explained by our new associations, we conducted additional analyses of our variants of interest in cohorts of diverse ancestry (Supplementary Table 16 ). In each of ten studies from four ancestry groups (EUR, AFR, ASN, and HISP), we ran a series of nested regression models to determine the relative contribution of each set of additional variables. The first model included only standard covariates (age, sex, center, principal components, etc.). The second model additionally included smoking status (both current and ever smoking). The third model added known variants [1] [2] [3] [4] [5] 12 . The fourth model added all new variants and the last model also included interaction terms for new variants. For the purpose of this analysis, new variants included the lead variant for each genome-widesignificant locus in the meta-analyses of stages 1 and 2 ( Table 1 ) and variants that were significant but only available in stage 1 meta-analyses (Table 2) . By subtracting r 2 values from each of these nested regression models, the proportion of variance explained by the additional set of variables was determined. We conducted these analyses by using two approaches. In approach 1, all variants with MAF ≥ 0.01 and imputation quality ≥ 0.3 were included in regression models. Although the imputation quality threshold used for the main analyses (≥0.5) was higher to reduce the risk of spurious associations, we selected a lower threshold for this secondary analysis to maximize the number of variants of interest included. In approach 2, to avoid possible overfitting, stepwise regression was used for variant selection, such that only variants that were associated (P < 0.05) were retained in the model. All variants were considered in models for each trait and ancestry group, regardless of the trait or ancestry group in which the association was identified.
Reproducing previously reported lipid associations. To evaluate the degree to which our data confirmed previous associations, we evaluated statistically significant associations reported from recent large meta-analyses [1] [2] [3] [4] [5] 12 . In the event of overlap between reports, the most statistically significant variant-trait association was considered, for a total of 356 unique associations for 279 variants. Output from our main-effect models (stage 1) was extracted for all ancestry groups for each previously reported variant-trait combination. Reproducibility was determined by P < 0.05/356 in any ancestry group and a consistent direction of effect (Supplementary Table 17 ).
Functional inference. To evaluate the degree to which our new variants might influence other cardiometabolic traits, we extracted our new variants (Tables 1  and 2 ) from previous studies. Supplementary Tables 19-24 present the association of these variants with coronary artery disease and myocardial infarction (data from the CARDIoGRAM Consortium 56 ), neurological traits (data from the Neurology Working Group of the CHARGE Consortium), anthropometric traits (data from the GIANT Consortium [57] [58] [59] ), adiposity × smoking interaction (data from the GIANT Consortium 60 ), diabetes and related traits (data from MAGIC 61 , AAGILE 62 , and DIAGRAM 63, 64 ), and kidney outcomes (data from the COGENT-Kidney Consortium 65 ). To conduct functional annotation of our new variants (Supplementary Tables  18 and 25 -27), we used NCBI Entrez gene (see URLs) for gene information, dbSNP to translate positions to human genome build 38, HaploReg (v4.1) and RegulomeDB for gene expression and regulation data from the ENCODE and Roadmap projects, and GTEx v7.0 for additional gene expression information. We also investigated our new variants in cis-and trans-eQTL data based on analysis of the whole blood of Framingham Heart Study participants 66 .
Pathway and gene set enrichment analyses. We conducted DEPICT analyses 13 on the basis of genome-wide-significant (P < 5 × 10 −8 ) variants separately for the three traits HDL, LDL, and triglycerides (Supplementary Tables 28-37) . To obtain input for prioritization and enrichment analyses, DEPICT first created a list of non-overlapping loci by applying a combined distance-and LD-based threshold (500-kb flanking regions and LD r² > 0.1) between the associated variants and 1000 Genomes reference data. DEPICT then obtained lists of overlapping genes by applying an LD-based threshold (r 2 > 0.5) between the non-overlapping variants and known functional coding or cis-acting regulatory variants for the respective genes. Finally, the major histocompatibility complex region on chromosome 6 (base positions 25,000,000-35,000,000) was removed from further analyses. DEPICT prioritized genes at associated regions by comparing functional similarity of genes across associated loci via a gene score that was adjusted for several confounders such as gene length. While using lead variants from 500 precompiled null GWAS, the scoring step was repeated 50 times to obtain an experiment-wide FDR for gene prioritization. Second, DEPICT conducted gene set enrichment analyses on the basis of a total of 14,461 precompiled reconstituted gene sets. The reconstituted gene sets involve 737 Reactome database pathways, 2,473 phenotypic gene sets (derived from the Mouse Genetics Initiative) 67 , 184 Kyoto Encyclopedia of Genes and Genomes (KEGG) database pathways, 5,083 Gene Ontology database terms, and 5,984 protein molecular pathways (derived from protein-protein interactions 68 ). Third, DEPICT conducted tissue and cell type enrichment analyses on the basis of expression data from any of the 209 MeSH annotations for 37,427 microarrays of the Affymetrix U133 Plus 2.0 array platform. In addition, we used the STRING database to identify protein-protein interactions.
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Sample size
As the degree to which gene x smoking interactions might influence lipids was unknown, but interactions are known to be challenging to detect because of statistical power limitations, we endeavored to aggregate as many samples as possible to improve our chances of discovery. We felt sufficiently confident in the sufficiency of our sample sizes because they exceeded those of previous efforts which detected gene x lifestyle interactions (for example: Manning AK, Nat Genet, 2012) and main effects of serum lipids (for example: Teslovich TM, Nature, 2010).
Data exclusions According to pre-established guidelines, individuals who were younger than 18 or older than 80 were excluded as the distribution of lipid values at these extremes of the aging spectrum, creating noisy data.
Replication
The promising associations in stage 1 analyses were evaluated in stage 2 analyses, comprised of independent samples. The main findings presented are of results of the meta-analyses of these two stages, however, the number of associations that replicated are given and further described in Supplemental Table 7 .
